Detalhe da pesquisa
1.
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Gynecol Oncol
; 182: 75-81, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262242
2.
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Gynecol Oncol
; 178: 27-35, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748268
3.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912
4.
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol
; 174: 34-41, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149903
5.
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Gynecol Oncol
; 167(3): 540-546, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36280455
6.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Int J Gynecol Cancer
; 32(12): 1576-1582, 2022 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368707
7.
Targeting obesity-related dysfunction in hormonally driven cancers.
Br J Cancer
; 125(4): 495-509, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33911195
8.
Bevacizumab in advanced endometrial cancer.
Gynecol Oncol
; 161(3): 720-726, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894982
9.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol
; 160(1): 71-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139041
10.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer
; 126(6): 1274-1282, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31880826
11.
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Gynecol Oncol
; 156(1): 194-202, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31757464
12.
Optimizing immunotherapy for gynecologic cancers.
Curr Opin Obstet Gynecol
; 32(1): 1-8, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31833942
13.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Nat Med
; 30(5): 1330-1338, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653864
14.
Comprehensive analysis of germline drivers in endometrial cancer.
J Natl Cancer Inst
; 115(5): 560-569, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36744932
15.
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Clin Cancer Res
; 28(19): 4302-4311, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849120
16.
Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.
Am J Hematol
; 91(2): E1, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26502013
17.
Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.
Gynecol Oncol Rep
; 37: 100844, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430690
18.
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
Gynecol Oncol Rep
; 38: 100873, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34926756
19.
Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness.
Clin Case Rep
; 8(2): 289-292, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32128175
20.
Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience.
Gynecol Oncol Rep
; 28: 120-123, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31011610